Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02737228
Recruitment Status : Active, not recruiting
First Posted : April 13, 2016
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
CrystalGenomics, Inc.

Brief Summary:

<Part I - Phase I trial>

The phase I clinical trial is to identify the MTD (Maximum Tolerated Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA in combination use of Gemcitabine and Erlotinib. Initial dose of CG200745 PPA is 187.5 mg/m^2, and it will be extended to 250 mg/m^2, 312.5 mg/m^2 or it will be reduced to 125 mg/m^2 based on the results of the cohort of 3 subjects per dose level.

Based on the 3+3 dose escalation study design, Gemcitabine and Erlotinib are administered as fixed doses, whereas CG200745 PPA is to be administered as in four different cohorts according to the dose level. Each cohort consists of 3 or 6 subjects.

<Part II - Phase II trial>

In the phase II clinical trial, the subjects will be administered with the dose which is to be identified as a recommended dose based on the results of Phase I study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment period is 6 cycles and tumor assessment is evaluated every 2 cycles.


Condition or disease Intervention/treatment Phase
Pancreatic Neoplasms Drug: CG200745 PPA Drug: Gemcitabine Drug: Erlotinib Phase 1 Phase 2

Detailed Description:

<Part I - Phase I trial>

The phase I clinical trial is to identify the MTD and DLT of CG200745 PPA in combination use of Gemcitabine and Erlotinib. Initial dose of CG200745 PPA is 187.5 mg/m^2, and it will be extended to 250 mg/m^2, 312.5 mg/m^2 or it will be reduced to 125 mg/m^2 based on the results of the cohort of 3 subjects per dose level.

Based on the 3+3 dose escalation study design, Gemcitabine and Erlotinib are administered as fixed doses, whereas CG200745 PPA is to be administered as in four different cohorts according to the dose level. Each cohort consists of 3 or 6 subjects.

  • Dose level 0: CG200745 PPA 125 mg/m^2 puls Gemcitabine 1000 mg/m^2) and Erlotinib 100 mg
  • Dose level 1: CG200745 PPA 187.5 mg/m^2 puls Gemcitabine 1000 mg/m^2) and Erlotinib 100 mg
  • Dose level 2: CG200745 PPA 250 mg/m^2 puls Gemcitabine 1000 mg/m^2) and Erlotinib 100 mg
  • Dose level 3: CG200745 PPA 312.5 mg/m^2 puls Gemcitabine 1000 mg/m^2) and Erlotinib 100 mg

<Part II - Phase II trial>

In the phase II clinical trial, the subjects will be administered with the dose which is to be identified as a recommended dose based on the results of Phase I study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment period is 6 cycles and tumor assessment is evaluated every 2 cycles.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Combination Therapy of CG200745 PPA With Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose (MTD) and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic Cancer
Study Start Date : March 2016
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : August 2019


Arm Intervention/treatment
Experimental: CG200745 PPA
CG200745 PPA plus Gemcitabine and Erlotinib
Drug: CG200745 PPA
CG200745 PPA IV every week three times per cycle (4 weeks)
Other Name: CG200745 PPA (phosphoric acid)

Drug: Gemcitabine
1000 mg/m^2 intravenously every week three times per cycle (4 weeks)
Other Name: combination therapy 1

Drug: Erlotinib
100 mg per oral daily per cycle (4 weeks)
Other Name: combination therapy 2




Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: up to 6 cycles (each cycle is 28 days) ]
    ORR is the proportion of the subjects with CR and PR in comparison to the total subjects at the final tumor assessment point (cycle 6) from the baseline


Secondary Outcome Measures :
  1. Disease control rate (DCR) [ Time Frame: up to 6 cycles (each cycle is 28 days) ]
    DCR is the proportion of the subjects with Complete Response (CR), Partial Response (PR), and stable disease (SD) in comparison to the total subjects at the final tumor assessment point (cycle 6) from the baseline

  2. Area Under the Curve [AUC] [ Time Frame: before the administration and up to 1440 mins after completion of the IP (Investigational Product) administration ]
    Pharmacokinetics (PK) parameter

  3. Maximum Plasma Concentration [Cmax] [ Time Frame: before the administration and up to 1440 mins after completion of the IP administration ]
    Pharmacokinetics (PK) parameter

  4. Adverse Events [ Time Frame: up to 6 cycles (each cycle is 28 days) ]
    safety parameter

  5. Clinical laboratory tests [ Time Frame: up to 6 cycles (each cycle is 28 days) ]
    safety parameter



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ages: ≥ 20 and ≤ 75 years
  • Subjects who join voluntarily for participation in the study, sign the consent form and are willing to comply the clinical trial procedure
  • Subjects who have diagnosed with unresectable, locally advanced, metastatic, histologically and cytologically confirmed pancreatic adenocarcinoma
  • ECOG (Eastern Cooperative Oncology Group) performance status: 0-2
  • Estimated life expectancy at the time of enrollment is more than 3 months
  • Adequate hematological, renal and hepatic function

    • Absolute neutrophil count (ANC) ≥ 1500/mm3, hemoglobin ≥ 9.0 g/dl (eligible if hemoglobin lab values are adjusted with blood transfusion), platelet ≥ 100,000/mm3
    • Within normal range of serum creatinine or creatinine clearance rate (CCr) ≥ 60 ml/min (using Cockcroft-Gault equation )
    • Subjects who have no abnormal serum electrolyte values (including calcium, magnesium, phosphorous and potassium). However, the supplementation therapy is allowed for normalization of serum electrolytes.

      ※ Normal reference range for Calcium: 8.3~10.5 mg/dl, Magnesium: 1.58~3.0 mg/dl, Phosphorous: 2.4~4.5 mg/dl, Potassium: 3.3~5.5 mmol/L

    • Serum bilirubin < 2 x Upper Limit Normal (ULN), Aspartate Aminotransferase (AST)/Alanine Aminotransferase (ALT) < 2.5 x ULN, Alkaline phosphatase (ALP) < 5 x ULN (If liver metastasis, AST/ALT <5 x ULN)
    • Prothrombin Time (PT) or Partial thromboplastin time (PTT) ≤ 1.5 x ULN (except for the use of anticoagulant, in this case, PT/PTT stabilization for up to 2 weeks should be confirmed)
  • No prior chemotherapy, radiation or biologics

Exclusion Criteria:

  • Subject who had experienced a major surgery within 2 weeks prior to the screening visit
  • Subject with an evidence for uncontrolled brain metastasis (except for the patients with radiologically and neurologically stable brain metastasis without corticosteroid therapy for at least two weeks)
  • Subject who cannot be administered oral drug, or have difficulty to absorb the study drugs due to a history of major gastrointestinal surgery or pathological findings.
  • Subjects who have treated antibiotics within last seven days due to an active bacterial infection prior to the enrollment. (Topical antibiotic therapies are excluded)
  • Subjects who had experienced any malignancies within past 5 years, except for basal cell skin cancer, in situ cervical cancer, or papillary thyroid tumor.
  • Pregnancy or Lactating
  • Fertile subjects who do not agree with the effective contraception during the study period and up to 3 months after the completion of the study. The following cases are exceptions: an irreversible and surgical sterility by hysterectomy, bilateral oophorectomy or bilateral salpingectomy, and menopausal women over 50 years old with no menstruation for at least 12 months and without hormonal therapy. Tubal ligation is not regarded as an effective contraception
  • Subject who cannot take anti-cancer chemotherapy due to a systemic disease (ex. chronic renal failure)
  • Subjects who have treated with any other investigational drug within 4 weeks prior to the screening visit
  • History of hypersensitivity to study drug
  • Subject with HIV positive

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02737228


Locations
Layout table for location information
Korea, Republic of
Yonsei University Health System
Seoul, Korea, Republic of
Sponsors and Collaborators
CrystalGenomics, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Siyoung Song, M.D., PhD. Yonsei University

Layout table for additonal information
Responsible Party: CrystalGenomics, Inc.
ClinicalTrials.gov Identifier: NCT02737228     History of Changes
Other Study ID Numbers: CG200745-2-03
First Posted: April 13, 2016    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Gemcitabine
Erlotinib Hydrochloride
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Protein Kinase Inhibitors